Short Interest Alert: Delmar Pharmaceuticals Incorporated (NASDAQ:DMPI) Stock Is Shorted More

December 1, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest Alert: Delmar Pharmaceuticals Incorporated (NASDAQ:DMPI) Stock Is Shorted More

The stock of Delmar Pharmaceuticals Incorporated (NASDAQ:DMPI) registered an increase of 63.52% in short interest. DMPI’s total short interest was 50,200 shares in December as published by FINRA. Its up 63.52% from 30,700 shares, reported previously. With 66,200 shares average volume, it will take short sellers 1 days to cover their DMPI’s short positions. The stock increased 1.00% or $0.04 on November 30, hitting $4.04. DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has risen 231.15% since April 28, 2016 and is uptrending. It has outperformed by 225.22% the S&P500.

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The company has a market cap of $42.42 million. The Firm focuses on the treatment of cancer. It currently has negative earnings. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme , a form of brain cancer.

DMPI Company Profile

DelMar Pharmaceuticals, Inc., incorporated on June 24, 2009, is a clinical-stage drug development company. The Firm focuses on the treatment of cancer. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. The Company’s drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications.

More notable recent DelMar Pharmaceuticals Inc (NASDAQ:DMPI) news were published by: Prnewswire.com which released: “DelMar Pharmaceuticals Delivers an Address and Presents an Overview of …” on November 21, 2016, also Prnewswire.com with their article: “DelMar Pharmaceuticals Presents New VAL-083 Data at Two International …” published on November 07, 2016, Prnewswire.com published: “DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations” on October 13, 2016. More interesting news about DelMar Pharmaceuticals Inc (NASDAQ:DMPI) were released by: Prnewswire.com and their article: “DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical …” published on April 19, 2016 as well as Prnewswire.com‘s news article titled: “DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and …” with publication date: June 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>